OM1:
WHAT: OM1, a leading real-world data, AI, and technology company with a focus on chronic diseases, today announced an upcoming poster presentation hosted by Dr. Carl Marci, OM1’s Chief Clinical Officer, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience. The poster will focus on the use of an AI based estimation model used to help characterize disease progression in multiple sclerosis (MS) subtypes using real-world data (RWD).
WHEN: The presentation will be held on the first day of ACTRIMS Forum 2024 on Thursday, February 29 between 6:00 – 7:30 pm ET.
WHY: To effectively monitor disease progression in patients with MS, the measurement of disability is an important component. The Expanded Disability Status Score (EDSS) is a validated, clinician-administered scale for measuring disability that is widely used in clinical trials, but it is recorded inconsistently in RWD sources. A previously developed AI and machine learning model was used to estimate EDSS (eEDSS) scores at discrete time points using routinely recorded, unstructured clinical notes from neurologists and applied to patients with MS in OM1’s Real-World Data Cloud.
The goal of the research is to assess the feasibility of using the eEDSS model to increase the number of available scores to support the characterization and understanding of disease progression in patients with relapsing remitting MS (RRMS) as they transition to secondary progressive MS (SPMS). The research and results showcase how the use of the model may improve the utility of RWD sources for MS research and inform the utility of subtyping MS and our understanding of disability during the transition from RRMS to SPMS.
Additional resources:
- For insights specific to OM1’s work with multiple sclerosis, including the company’s PremiOM MS dataset, visit the website page here.
- To learn more about OM1’s real-world data, AI, and integrated evidence platforms and insights, please email info@om1.com.
- Connect with OM1 via LinkedIn and Twitter.
ABOUT:
With specialization in chronic conditions, OM1 is re-imagining real-world evidence and insights by developing large electronically connected networks of clinicians and health data in dermatology, rheumatology, gastroenterology, cardiology, metabolism, respiratory, mental health, neurology and other specialty areas. Leveraging its data automation platform, OM1 Aspen, extensive clinical networks and artificial intelligence (AI) platform, PhenOM™, OM1 offers industry-leading enriched healthcare datasets, retrospective and prospective studies, advanced analytics, and AI-driven guidelines adherence and decision-support around diagnosis, risk management, and treatment. With a focus on high-quality data and clinical outcomes, the offerings are used for accelerating research, demonstrating treatment effectiveness, supporting regulatory submissions, monitoring safety, and informing commercialization.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227590516/en/